The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial.
 
Daniel Morgensztern
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Genentech; Heat Biologics
Speakers' Bureau - Boehringer Ingelheim; Genentech
Research Funding - AstraZeneca (Inst); Baxter (Inst); Celgene (Inst); Clovis Oncology (Inst); Heat Biologics (Inst); Incyte (Inst); Merck (Inst); Newlink Genetics (Inst); Stem CentRx (Inst)
 
Wael A. Harb
No Relationships to Disclose
 
Kurt Alex Schalper
No Relationships to Disclose
 
Melissa Leigh Price
Employment - Heat Biologics
Leadership - Heat Biologics
Stock and Other Ownership Interests - Heat Biologics
Travel, Accommodations, Expenses - Heat Biologics
 
Brandon Early
Employment - Heat Biologics
Stock and Other Ownership Interests - Heat Biologics
 
Taylor Houghton Schreiber
Employment - Heat Biologics
Leadership - Heat Biologics
Stock and Other Ownership Interests - Heat Biologics
Research Funding - Heat Biologics